Phase II Trial of Alisertib in Combination with Irinotecan and Temozolomide for Patients with Relapsed or Refractory Neuroblastoma

Steven G. DuBois(Dana-Farber/Boston Children's Cancer and Blood Disorders Center), Araz Marachelian(University of Southern California), Hiroyuki Shimada(Children's Hospital of Los Angeles), Rachel A. Kudgus(Mayo Clinic), Julie R. Park(Seattle Children's Hospital), Katherine K. Matthay(University of California, San Francisco), Najee Boucher(Children's Hospital of Los Angeles), Joel M. Reid(Children's Hospital of Philadelphia), Yaël P. Mossé(Children's Hospital of Philadelphia), Clare J. Twist(Children's Hospital of Los Angeles), Scarlett Czarnecki(Children's Hospital of Los Angeles), Susan L. Cohn(Comer Children's Hospital), Rochelle Bagatell(Children's Hospital of Philadelphia), Brian Weiss(Cincinnati Children's Hospital Medical Center), Elizabeth Fox(Children's National), Meaghan Granger(Cook Children's Medical Center), Jesse Courtier(UCSF Benioff Children's Hospital), Lars M. Wagner(Cincinnati Children's Hospital Medical Center), Margaret E. Macy(Morgan Adams Foundation), Denice Tsao‐Wei(Children's Hospital of Los Angeles), Susan Groshen(American Society of Clinical Oncology), Hollie Lai(Children's Hospital of Orange County), Kelly C. Goldsmith(Children's Healthcare of Atlanta), Randall A. Hawkins(UCSF Benioff Children's Hospital), Renee M. McGovern(Mayo Clinic), Chunqiao Luo(Children's Hospital of Los Angeles), Fariba Goodarzian(University of Southern California), Greg Yanik(C. S. Mott Children's Hospital), John M. Maris(Children's Hospital of Philadelphia)
Clinical Cancer Research
August 9, 2018
Cited by 88


Related Papers